Tolerance induction using lentiviral gene delivery delays onset and severity of collagen II arthritis

Molecular Therapy

Volumn 17, Issue 4, 2009, Pages 632-640

  Gjertsson, Inger ^a   Laurie, Karen L ^b   Devitt, James ^b   Howe, Steven J ^b   Thrasher, Adrian J ^b   Holmdahl, Rikard ^c   Gustafsson, Kenth ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; LENTIVIRUS VECTOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN PRESENTING CELL; ARTICLE; BYSTANDER EFFECT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; DRUG TOLERANCE; GENE EXPRESSION; GENE INDUCTION; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; GLYCOSYLATION; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IN VIVO GENE TRANSFER; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM;

MUS;

EID: 63949083969     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.299     Document Type: Article

References (44)

1. Fernando, MM, Stevens, CR, Walsh, EC, De Jager, PL, Goyette, P, Plenge, RM et al. (2008). Defining the role of the MHC in autoimmunity: A review and pooled analysis. PLoS Genet 4: E1000024.
2. Backlund, J, Carlsen, S, Hoger, T, Holm, B, Fugger, L, Kihlberg, J et al. (2002). Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci USA 99: 9960-9965.
3. Cook, AD, Rowley, MJ, Mackay, IR, Gough, A and Emery, P (1996). Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression. Arthritis Rheum 39: 1720-1727.
4. Corrigall, VM, Bodman-Smith, MD, Fife, MS, Canas, B, Myers, LK, Wooley, P et al. (2001). The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J Immunol 166: 1492-1498.
5. Fritsch, R, Eselbock, D, Skriner, K, Jahn-Schmid, B, Scheinecker, C, Bohle, B et al. (2002). Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis. J Immunol 169: 1068-1076.
6. Boissier, MC, Chiocchia, G, Texier, B and Fournier, C (1989). Pattern of humoral reactivity to type II collagen in rheumatoid arthritis. Clin Exp Immunol 78: 177-183.
7. Corrigall, VM and Panayi, GS (2002). Autoantigens and immune pathways in rheumatoid arthritis. Crit Rev Immunol 22: 281-293.
8. Kim, WU, Cho, ML, Jung, YO, Min, SY, Park, SW, Min, DJ et al. (2004). Type II collagen autoimmunity in rheumatoid arthritis. Am J Med Sci 327: 202-211.
9. Wang, D, Hill, JA, Cairns, E and Bell, DA (2002). The influence of HLA-DR4 (0401) on the immune response to type II collagen and the development of collagen induced arthritis in mice. J Autoimmun 18: 95-103.
10. Cho, YG, Cho, ML, Min, SY and Kim, HY (2007). Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun Rev 7: 65-70.
11. Scheinecker, C, Redlich, K and Smolen, JS (2008). Cytokines as therapeutic targets: Advances and limitations. Immunity 28: 440-444.
12. Chin, RK, Zhu, M, Christiansen, PA, Liu, W, Ware, C, Peltonen, L et al. (2006). Lymphotoxin pathway-directed, autoimmune regulator-independent central tolerance to arthritogenic collagen. J Immunol 177: 290-297.
13. Trentham, DE, Dynesius-Trentham, RA, Orav, EJ, Combitchi, D, Lorenzo, C, Sewell, KL et al. (1993). Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261: 1727-1730.
14. Barnett, ML, Kremer, JM, St Clair, EW, Clegg, DO, Furst, D, Weisman, M et al. (1998). Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 41: 290-297.
15. Choy, EH, Scott, DL, Kingsley, GH, Thomas, S, Murphy, AG, Staines, N et al. (2001). Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum 44: 1993-1997.
16. Nagler-Anderson, C, Bober, LA, Robinson, ME, Siskind, GW and Thorbecke, GJ (1986). Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci USA 83: 7443-7446.
17. Tarkowski, A, Sun, JB, Holmdahl, R, Holmgren, J and Czerkinsky, C (1999). Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine. Arthritis Rheum 42: 1628-1634.
18. Rosloniec, EF, Whittington, KB, Zaller, DM and Kang, AH (2002). HLA-DR1 (DRB1*0101) and DR4 (DRB1*0401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen. J Immunol 168: 253-259.
19. Andersson, EC, Hansen, BE, Jacobsen, H, Madsen, LS, Andersen, CB, Engberg, J et al. (1998). Definition of MHC and T cell receptor contacts in the HLA-DR4 restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice. Proc Natl Acad Sci USA 95: 7574-7579.
20. Dessen, A, Lawrence, CM, Cupo, S, Zaller, DM and Wiley, DC (1997). X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 7: 473-481.
21. Diab, BY, Lambert, NC, L'Faqihi, FE, Loubet-Lescoulie, P, de Preval, C and Coppin, H (1999). Human collagen II peptide 256-271 preferentially binds to HLA-DR molecules associated with susceptibility to rheumatoid arthritis. Immunogenetics 49: 36-44.
22. Kjellen, P, Brunsberg, U, Broddefalk, J, Hansen, B, Vestberg, M, Ivarsson, I et al. (1998). The structural basis of MHC control of collagen-induced arthritis; binding of the immunodominant type II collagen 256-270 glycopeptide to H-2Aq and H-2Ap molecules. Eur J Immunol 28: 755-767.
23. Michaelsson, E, Andersson, M, Engstrom, A and Holmdahl, R (1992). Identification of an immunodominant type-II collagen peptide recognized by T cells in H-2q mice: Self tolerance at the level of determinant selection. Eur J Immunol 22: 1819-1825.
24. Rosloniec, EF, Whittington, KB, Brand, DD, Myers, LK and Stuart, JM (1996). Identification of MHC class II and TCR binding residues in the type II collagen immunodominant determinant mediating collagen-induced arthritis. Cell Immunol 172: 21-28.
25. Koch, N, van Driel, IR and Gleeson, PA (2000). Hijacking a chaperone: manipulation of the MHC class II presentation pathway. Immunol Today 21: 546-550.
26. Fujii, S, Senju, S, Chen, YZ, Ando, M, Matsushita, S and Nishimura, Y (1998). The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells. Hum Immunol 59: 607-614.
27. Srinivasakumar, N (2001). HIV-1 vector systems. Somat Cell Mol Genet 26: 51-81.
28. Corthay, A, Backlund, J, Broddefalk, J, Michaelsson, E, Goldschmidt, TJ, Kihlberg, J et al. (1998). Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. Eur J Immunol 28: 2580-2590.
29. Garcia, G, Komagata, Y, Slavin, AJ, Maron, R and Weiner, HL (1999). Suppression of collagen-induced arthritis by oral or nasal administration of type II collagen. J Autoimmun 13: 315-324.
30. Higuchi, K, Kweon, MN, Fujihashi, K, McGhee, JR and Kiyono, H (2000). Comparison of nasal and oral tolerance for the prevention of collagen induced murine arthritis. J Rheumatol 27: 1038-1044.
31. Honda, A, Ametani, A, Matsumoto, T, Iwaya, A, Kano, H, Hachimura, S et al. (2004). Vaccination with an immunodominant peptide of bovine type II collagen induces an anti-TCR response, and modulates the onset and severity of collagen-induced arthritis. Int Immunol 16: 737-745.
32. Khare, SD, Krco, CJ, Griffiths, MM, Luthra, HS and David, CS (1995). Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis. J Immunol 155: 3653-3659.
33. Staines, NA, Harper, N, Ward, FJ, Malmstrom, V, Holmdahl, R and Bansal, S (1996). Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin Exp Immunol 103: 368-375.
34. Zhu, P, Li, XY, Wang, HK, Jia, JF, Zheng, ZH, Ding, J et al. (2007). Oral administration of type-II collagen peptide 250-270 suppresses specific cellular and humoral immune response in collagen-induced arthritis. Clin Immunol 122: 75-84.
35. Dzhambazov, B, Nandakumar, KS, Kihlberg, J, Fugger, L, Holmdahl, R and Vestberg, M (2006). Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules. J Immunol 176: 1525-1533.
36. Evans, CH, Ghivizzani, SC and Robbins, PD (2006). Gene therapy for arthritis: What next? Arthritis Rheum 54: 1714-1729.
37. Adriaansen, J, Vervoordeldonk, MJ and Tak, PP (2006). Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology (Oxford) 45: 656-668.
38. Pan, D, Gunther, R, Duan, W, Wendell, S, Kaemmerer, W, Kafri, T et al. (2002). Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol Ther 6: 19-29.
39. Lan, RY, Ansari, AA, Lian, ZX and Gershwin, ME (2005). Regulatory T cells: Development, function and role in autoimmunity. Autoimmun Rev 4: 351-363.
40. Li, MO, Wan, YY, Sanjabi, S, Robertson, AK and Flavell, RA (2006). Transforming growth factor-β regulation of immune responses. Annu Rev Immunol 24: 99-146.
41. Thorbecke, GJ, Shah, R, Leu, CH, Kuruvilla, AP, Hardison, AM and Palladino, MA (1992). Involvement of endogenous tumor necrosis factor alpha and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 89: 7375-7379.
42. Levine, BL, Humeau, LM, Boyer, J, MacGregor, RR, Rebello, T, Lu, X et al. (2006). Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 103: 17372-17377.
43. Demaison, C, Parsley, K, Brouns, G, Scherr, M, Battmer, K, Kinnon, C et al. (2002). High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13: 803-813.
44. Verdrengh, M, Jonsson, IM, Holmdahl, R and Tarkowski, A (2003). Genistein as an anti-inflammatory agent. Inflamm Res 52: 341-346.